Drugs / ZL-6201
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07374848 | Mar 2026 → Aug 2028 expected | sarcoma | Zai Lab (Shanghai) Co., Ltd. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-04-25 | Zai Lab (Shanghai) Co., Ltd. | Results Zai Lab Presents Data Highlighting Potential of Internally Developed, Next-Generation Oncology Therapies at AACR 2025 zailaboratory.com ↗
Findings support advancement of ZL-6201 into Investigational New Drug (IND)-enabling studies in 2025 as a potential first-in-class and best-in-class antibody-drug conjugate (ADC) treatment for patients with leucine-rich repeat-containing protein 15 (LRRC15)-positive solid tumors |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2025-04-25 | Zai Lab (Shanghai) Co., Ltd. | Zai Lab Presents Data Highlighting Potential of Internally Developed, Next-Generation Oncology Therapies at AACR 2025 zailaboratory.com ↗ |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ZL-6201 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07374848 ↗ |